As an important part of the large CE-marking project, the company will soon receive its first delivery of CE-marked treatment kits intended for IQwave™ and D-EECT treatment from its manufacturer.
Even though the company has not completed the certification of the entire IQwave™ system, it is very gratifying that we have reached this intermediate goal. The approval also facilitates sales to state hospitals in both India and the Philippines.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 [email protected]
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: [email protected]
This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Friday August 14 2020 at 08.50 (CET).
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
(c) 2020 Cision. All rights reserved., source Press Releases - English